Research Paper Volume 14, Issue 4 pp 1822—1835
Downregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation
- 1 Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 2 Department of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China
- 3 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 4 Department of Orthopedic Surgery, The Second Hospital University of South China, Hengyang 421001, Hunan, China
- 5 Department of Emergency, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 6 Department of Emergency, Xiangya Changde Hospital, Changde 415000, Hunan, China
- 7 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Received: January 7, 2022 Accepted: February 15, 2022 Published: February 21, 2022
https://doi.org/10.18632/aging.203905How to Cite
Copyright: © 2022 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Exosome has been demonstrated to be secreted from cells and seized by targeted cells. Exosome could transmit signals and exert biological functions in cancer progression. Nevertheless, the underlying mechanisms of exosome in ovarian cancer (OC) have not been fully explored. In this study, we wanted to explore whether Fibroblast growth factor 9 (FGF9), as an exosome-associated gene, was importantly essential in OC progression and prognosis. Firstly, comprehensive bioinformatics platforms were applied to find that FGF9 expression was lower in OC tissues compared to normal ovarian tissues. Meanwhile, downregulated FGF9 displayed favorable prognostic values in OC patients. The gene enrichment of biological functions indicated that abnormally expressed FGF9 could be involved in the OC-related immune signatures, such as immunoinhibitors and chemokine receptors. Taken together, these findings could provide a novel insight into the significance of FGF9 in OC progress and supply a new destination of FGF9-related immunotherapy in clinical treatment.